HiFiBiO Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- HiFiBiO Therapeutics's estimated annual revenue is currently $17.4M per year.
- HiFiBiO Therapeutics's estimated revenue per employee is $155,000
- HiFiBiO Therapeutics's total funding is $179.5M.
Employee Data
- HiFiBiO Therapeutics has 112 Employees.
- HiFiBiO Therapeutics grew their employee count by 0% last year.
HiFiBiO Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Head Research, France & Global CMC | Reveal Email/Phone |
2 | Senior Director, Head US Drug Intelligent Science and External Innovation | Reveal Email/Phone |
HiFiBiO Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4M | 26 | -30% | N/A | N/A |
#2 | $5.9M | 38 | 9% | N/A | N/A |
#3 | $3.4M | 22 | 0% | N/A | N/A |
#4 | $1.2M | 15 | -62% | €100.3M | N/A |
#5 | $14.7M | 95 | 1% | $121M | N/A |
#6 | $3.3M | 21 | -19% | N/A | N/A |
#7 | $10.1M | 65 | 18% | N/A | N/A |
#8 | $4.2M | 27 | 17% | $6.56M | N/A |
#9 | $6.7M | 43 | 10% | N/A | N/A |
#10 | $4M | 26 | -33% | N/A | N/A |
What Is HiFiBiO Therapeutics?
HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For more information, please visit www.hifibio.com. HiFiBiO Therapeutics has operations in Paris, France, Cambridge, MA, USA and Hangzhou, China.
keywords:N/A
$179.5M
Total Funding
112
Number of Employees
$17.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
HiFiBiO Therapeutics News
... how to apply this concept to humans from a therapeutic perspective. ... (CNRS/ESPCI Paris - PSL) and from company HiFiBio Therapeutics.
HiFiBiO Therapeutics has raised $75 million in a Series D led by Mirae Asset Financial Group. Founded in 2013, the company is a developer of single-cell profiling technologies designed to accelerate biotherapeutics that combat cancer and autoimmune disorders. Select Additional Investors B Capi ...
HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a Korean global financial services group with $563 billion in asset ...
Premium HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a Korean global financial services group with $563 billion ...
Other Companies in Paris
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.2M | 112 | 7% | N/A |
#2 | $15.7M | 112 | 26% | N/A |
#3 | $19.6M | 112 | 8% | N/A |
#4 | $23.5M | 112 | 24% | N/A |
#5 | $28.4M | 112 | 12% | N/A |